miR-132 mediates a metabolic shift in prostate cancer cells by targeting Glut1

Wei Qu1, Shi-mei Ding2, Gang Cao3, She-jiao Wang1, Xiang-hong Zheng1 and Guo-hui Li1

1 Department of Nuclear Medicine, The Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Shaanxi, China
2 Department of Endocrinology, The Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Shaanxi, China
3 Department of General Surgery, The Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, Shaanxi, China

Keywords
Glut1; glycolysis; miR-132; prostate cancer cell

Correspondence
G. Cao, The Second Affiliated Hospital of Medical School of Xi’an Jiaotong University, 157 Xiwu Road, Xi’an, Shaanxi 710004, China
E-mail: gangcao365@163.com

(Received 12 January 2016, revised 9 April 2016, accepted 2 May 2016

doi:10.1002/2211-5463.12086

Prostate cancer is the second leading cause of cancer-related deaths among men worldwide. Early diagnosis increases survival rates in patients but the survival rate has remained relatively poor over the past years. Increasing evidence shows that altered metabolism is a critical hallmark in prostate cancer. There is a strong need to explore the molecular mechanisms underlying cancer metabolism for prostate cancer therapy. Whether the aberrant expression of microRNA (miRNA) contributes to cancer metabolism is not fully known. In this study, we found that microRNA-132 (miR-132) expression is reduced and thus leads to a metabolic switch in prostate cancer cells. miR-132 performs this role by increasing Glut1 expression, resulting in the enhanced rate of lactate production and glucose uptake. The altered metabolism induced by decreased miR-132 levels confers the rapid growth of the cancer cells. These data indicate that miR-132 is involved in regulating the Warburg effect in prostate cancer by inhibiting Glut1 expression.

Prostate cancer affects one in nine men over the age of 65 and represents the most commonly diagnosed cancer in American men [1]. Although radiation and surgery are generally effective for the majority of men, the prognosis remains poor in patients with progressive disease [2]. Prostate cancer cells, in particular, are exquisitely sensitive to metabolic changes and to cancer genes that alter metabolic homeostasis [3,4]. A distinct set of genes, proteins, and metabolites orchestrate cancer progression from a precursor lesion to localized disease and finally to metastatic cancer [5]. Although gene and protein expression profiles have been extensively studied in prostate cancer, little is known about how prostate cancer cells undergo a metabolic switch or reprogramming. Understanding the metabolic shift in prostate cancer is a key step in the development of new and effective therapeutic approaches.

Altered metabolism is a common feature of cancer cells [6]. Normally, noncancerous cells rely primarily on oxidative phosphorylation in the mitochondria to generate adenosine triphosphate for cellular physiology; however, even in the presence of sufficient oxygen, rapidly proliferating cancer cells metabolize large amounts of glucose for lactate, ATP production, carbohydrates, and nucleic acids [7]. This phenomenon is known as the ‘Warburg effect’. Tumor cells reprogram their metabolic pathway to meet the rapid growth needs including nucleic acids and glycolytic intermediates. As a result, the metabolic shift toward aerobic glycolysis in cancer cells is believed to be due to the increased demand to support the rapid growth of cancer cells [8]. There is an increasing amount of evidence showing that reprogrammed cancer metabolism is a potential target in cancer therapy.

microRNA (miRNA) are endogenous noncoding RNA composed of 18–24 nucleotides that regulate gene expression at the post-transcriptional level in a sequence-specific manner [9]. miRNA negatively

Abbreviations
2-DG, 2-deoxyglucose; 3’ UTR, 3’-untranslated regions; Glut1, glucose transporter 1; IDH3a, isocitrate dehydrogenase 3 (NAD+) alpha; qRT-PCR, quantitative reverse transcription polymerase chain reaction.
suppress gene expression by complementarily binding to the 3'-untranslated regions (3'UTR) that results in the degradation of target mRNA or the repression of mRNA translation [10]. Most miRNA are first transcribed by RNA polymerase II as pre-miRNA, which are characterized by hairpin structures and are subsequently processed in the nucleus into long precursor miRNA (pre-miRNA). The pre-miRNA are exported to the cytoplasm by exportin-5 and are further cleaved into mature miRNA [11].

miRNA, which are frequently aberrantly expressed in different types of cancer, have been reported to play a critical role in tumorigenesis, including processes such as proliferation, cell cycle, apoptosis, differentiation, and migration. Recently, emerging evidence has shown that a large group of miRNA were reported to function as key natural regulators in cancer cell metabolism [11]. For example, miR-424 regulates metabolic function in prostate cancer cell migration. miR-181a reprogramming in cancer-associated fibroblasts by altering the expression of IDH3a [12]. miR-181a mediates a metabolic shift in colon cancer cells via the PTEN/AKT pathway [13]. miR-33a and miR-33b play a critical function in regulating cholesterol homeostasis and fatty acid degradation [14].

Recently, there has been an increasing research interest on the role of miR-132 in tumorigenesis and cancer treatment. Studies have identified that higher miR-132 expression could be used as a biomarker of poor prognosis in patients diagnosed with glioma [15]. Another group showed that miR-132 may participate in the tumor progression of osteosarcoma, and loss of miR-132 expression may be a predictor of unfavorable outcomes in patients with osteosarcoma [16]. A report by Zhang B et al. found that miR-132 represses nonsmall cell lung cancer growth by inducing apoptosis, a process that is independent of acetylcholinesterase [17].

However, the direct function of miR-132 in prostate cancer cells has not been reported. In our study, we report that miR-132 is significantly reduced in prostate cancer cells. The loss of function of miR-132 enhances cell proliferation via enhanced glycolysis by directly binding to the 3'-UTR of Glut1.

**Materials and methods**

**Cell culture**

PC-3, DU-145, and HEK293T cells were purchased from the American Type Culture Collection (ATCC) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat-inactivated FBS (Invitrogen, Carlsbad, CA, USA), 100 units-mL⁻¹ penicillin/streptomycin and 4.5 g·L⁻¹ glucose in a tissue incubator maintained at 37 °C.

**Transfections**

All transient transfections were carried out using Lipofectamine 2000 reagent as described previously (Invitrogen) according to the manufacturer’s protocol. Transient transfection of microRNA-132 mimics, microRNA-132 inhibitor, scramble, and Glut1 siRNA (5'-UAUUAACACAGACACUUA-3') at a final concentration of 20 nm was accomplished with lipofectamine 2000 according to the manufacturer’s protocol.

**Luciferase reporter assay**

The method for the luciferase reporter assay was described previously. Briefly, HEK293T cells were seeded into 96-well plates and were transfected with 20 nm mimics along with reporter vectors at 100 ng-well⁻¹. Luciferase activity was measured after 48 h of transfection using the dual-luciferase reporter assay system according to the manufacturer’s instructions. Luciferase activity was normalized to Renilla luciferase expression. The assay was performed in duplicate, and at least three independent experiments were performed.

**Western blots**

Cells were homogenized and lysed in RIPA buffer supplemented with a protease inhibitor cocktail. Protein levels were quantified using the bicinchoninic acid assay kit, and proteins were then separated using an 8% SDS/PAGE gel. Proteins were transferred to a nitrocellulose membrane, which was blocked with 5% nonfat milk and subsequently exposed to the primary antibody. The indicated proteins were detected with an enhanced chemiluminescence kit.

**Cell viability assays**

Cells were seeded at a density of 5000 cells/96-well in DMEM medium and transfected with miR-132 mimics or miR-132 inhibitor. After 48 h, the cells were treated with AlamarBlue Cell Viability Reagent (ThermoFisher Scientific, Grand Island, NY, USA) for 4 h at 37 °C. Cell viability was measured at 560 nm excitation/590 nm emission filter set.

**Colony formation assays**

Cells transfected with miR-132 mimics, miR-132 inhibitor or scramble controls were examined for colony-forming ability. Five hundred cells were seeded in six-well plates and were allowed to grow for up to 7 days without being disturbed. After fixation by 70% ethanol, cells were stained with 0.5% crystal violet, and the cell colonies were subsequently counted.
Measurement of glucose uptake and extracellular lactate secretion

The miR-132 mimics or the miR-132 inhibitor were transiently transfected into prostate cancer cells. The cell medium was harvested after transfection for 48 h. Glucose uptake was measured using a colorimetric assay according to the manufacturer’s instructions (Glucose Uptake Colorimetric Assay Kit; BioVision, Milpitas, CA, USA). Lactate production was measured using the lactate assay kit (Sigma-Aldrich, Saint Louis, MO, USA).

Analysis of miR-132 expression in GSE36802 dataset

The NCBI Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) was used to analyze miR-132 expression in prostate cancer compared with normal tissues [18]. Each dataset was log2 transformed, median normalized. The miR-132 expression level of individual transcripts were subsequently examined across all the sample datasets.

Statistical analysis

All values were expressed as the mean ± SD. Statistical analysis was performed using PRISM 5.0 software (GraphPad, San Diego, CA, USA) using a two-tailed Student’s t-test. P < 0.05 was considered statistically significant for all analyses.

Results

miR-132 levels are decreased in prostate cancer cells

To explore the expression of miR-132 in prostate cancer cells, we downloaded a published dataset (Gene expression omnibus accession GSE36802) [18] and analyzed the miR-132 expression in prostate cancer cells. The data indicated that miR-132 was markedly lower in prostate cancer tissue compared with normal tissue, with a P value of 0.026 (Fig. 1A). Next, we confirmed the expression of miR-132 in prostate cancer cell lines. qRT-PCR results showed that miR-132 expression is significantly lower in prostate cancer cell lines compared with the normal prostate cell line, PNT2 (Fig. 1B).

miR-132 suppresses proliferation of prostate cancer cells

To examine the biological function of miR-132 on the proliferation of prostate cancer cells, we transfected the miR-132 mimic or the miR-132 inhibitor into prostate cancer cells at a total of 20 nM. The qRT-PCR analysis showed that miR-132 expression was significantly increased in the miR-132 mimic-transfected groups and reduced in the miR-132 inhibitor-transfected groups (Fig. 2A). The cell proliferation assay by accounting cell numbers demonstrated that cell growth was decreased in miR-132 overexpression prostate cancer cells compared with the control cells (Fig. 2B). To further explore whether the inhibition of miR-132 in prostate cancer cells increased cell growth, knockdown of miR-132 in prostate cancer cells transfected with the miR-132 inhibitor enhanced cell growth as expected (Fig. 2B). The colony formation assay also showed that the gain of function of miR-132 enhances prostate cancer colony formation, while loss of function of miR-132 inhibits prostate cancer colony formation (Fig. 2C,D). In conclusion, these data suggest that downregulation of miR-132 enhanced cell growth in prostate cancer cell.

Reduction in miR-132 expression induces a metabolic switch in prostate cancer cells

We further explored whether reduced expression of miR-132 was capable of inducing a metabolic switch
in prostate cancer cells. Knockdown of miR-132 expression in prostate cancer cells increased glucose uptake rate and lactate secretion (Fig. 3A, B). In contrast, overexpression of miR-132 in prostate cancer cells transfected with miR-132 mimics decreased the rate of glucose uptake and lactate secretion (Fig. 3A, B). Western blot analysis showed that, compared with control cells, the HK2 and PKM2 proteins, which are
two key proteins involved in glycolysis, were increased in cells treated with the miR-132 inhibitor (Fig. 3C).

To examine whether a miR-132-induced metabolic shift is required for cell proliferation, we treated prostate cancer cells transfected with the miR-132 inhibitor with 2-deoxyglucose (2-DG), a glucose analog that suppresses glycolysis by binding to hexokinase, and subsequently performed a cell proliferation assay with alamarBlue assay. The data demonstrated that the repression of glycolysis induced by the miR-132 inhibitor is sufficient to inhibit cell growth (Fig. 3D). Taken together, these data show that miR-132-induced glycolysis is required for increased cell growth.

**miR-132 represses Glut1 expression by directly targeting its 3’UTR**

We used two different mRNA target-predicting algorithms (miRanda; TargetScan, www.targetscan.org) to predict the potential targets of miR-132. Candidate genes involved in glycolysis were of interest. The result showed that an area within the 3’UTR of Glut1 might be a potential target of miR-132 (Fig. 4A). The data from the western blot analysis confirmed that overexpression of miR-132 suppressed Glut1 at the protein level (Fig. 4C), while knockdown of miR-132 increased the expression of Glut1 (Fig. 4C). To explore whether miR-132 regulated Glut1 at the mRNA level, we analyzed the mRNA levels of Glut1 using real-time PCR. The results showed that knockdown of miR-132 significantly increased the Glut1 mRNA levels (Fig. 4B). Next, to test whether Glut1 is a direct downstream target of miR-132, we performed a luciferase reporter assay. The results indicated that miR-132 significantly repressed the luciferase activity in the wild-type group, when the four nucleotides in red were mutated into their complimentary nucleotides (Fig. 4A), miR-132 could no longer affect the luciferase activity (Fig. 4D).
To detect whether Glut1 is required for miR-132 in regulating cell proliferation, we knocked down the expression of Glut1 in PC3 cells transfected with miR-132 inhibitor and then analyzed the cell proliferation. The results showed that siRNA obviously decreases Glut1 protein level in PC3 cells treated with miR-132 inhibitor (Fig. 4E). As expected, the alarma blue assay showed that the increased proliferation rate induced by miR-132 is suppressed by Glut1 knockdown (Fig. 4F). Taken together, the data indicated that miR-132 inhibits the expression of Glut1 by directly binding to the 3’UTR.

Discussion

miRNA have gained increasing attention due to their critical roles in many biological processes, including cell cycle, proliferation, differentiation, cell motility and apoptosis, and in the metabolic switch [19]. Several miRNA and their targets have been shown to be abnormally expressed in prostate cancer, leading to the development, invasion, and metastasis of this disease [20]. The altered expression of miRNA is useful as biomarkers for the diagnosis, prognosis, and classification of prostate cancer [21,22]. Thus, understanding the characteristic miRNA abnormalities could contribute to the development of novel therapeutic strategies in prostate cancer.

Recently, the aberrant expression of miR-132 was associated with different types of human cancers. Significant downregulation of miR-132 has been shown in pituitary tumors, breast cancer, and primary osteosarcoma [16,23,24]; however, the function of miR-132 in prostate cancer cell tumorigenesis remains unclear.

In this study, we are the first to report that miR-132 expression was reduced in prostate cancer tissues compared with adjacent normal tissues. Previous studies have shown that miR-132 inhibits cell proliferation by acting as a tumor suppressor in osteosarcoma and breast cancer. Consistent with the previous data, our data from the alarma blue assay indicated that miR-132 reduced cell growth in prostate cancer.

The molecular mechanism underlying altered metabolism is complicated and not fully understood. In our study, we showed that miR-132 is involved in regulating the aerobic metabolism in prostate cancer cells. Inhibition of miR-132 enhances lactate secretion and glucose uptake, while overexpression of miR-132 reduces lactate secretion and glucose uptake. miR-132-induced metabolism is required for prostate cancer cell growth. In addition, we showed that Glut1 is a direct downstream target of miR-132. Downregulation of miR-132 in prostate cancer cells needs to be extensively investigated for its role in cancer cell metabolism.

In conclusion, our study reveals new insight that reduction in miR-132 in prostate cancer cells enhances aerobic glycolysis by regulating Glut1 expression, thus promoting cell proliferation. These data identify miR-132 as a molecule involved in the regulation of the Warburg effect in prostate cancer cells and as a potential therapeutic target for prostate cancer.

Author contributions

WQ, SD performed most of the experiments; SW, XZ, GL performed some of the experiments. Gang Cao wrote the manuscript. All the authors have read this manuscript.

References

1. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT et al. (2013) The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15, 491–501.
2. Costello LC and Franklin RB (2006) The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 5, 17.
3. Sadeghi RN, Karami-Tehrani F and Salami S (2015) Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes. Tumour Biol 36, 2893–2905.
4. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Perald i S, Cormont M, Bertolotto C et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70, 2465–2475.
5. Peck B and Schulze A (2014) Cholesteryl esters: fueling the fury of prostate cancer. Cell Metab 19, 350–352.
6. Hsu PP and Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134, 703–707.
7. Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13, 472–482.
8. Cairns RA, Harris IS and Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11, 85–95.
9. Mitra R, Sun J and Zhao Z (2015) microRNA regulation in cancer: one arm or two arms? Int J Cancer 137, 1516–1518.
10. Sarode SC, Sarode GS and Patil S (2014) MicroRNA in oral cancer research: future prospects. J Contemp Dent Pract 15, i–ii.
11 Tomasetti M, Santarelli L, Neuzil J and Dong L (2014) MicroRNA regulation of cancer metabolism: role in tumour suppression. *Mitochondrion* **19**(Pt A), 29–38.
12 Zhang D, Wang Y, Shi Z, Liu J, Sun P, Hou X, Zhang J, Zhao S, Zhou BP and Mi J (2015) Metabolic reprogramming of cancer-associated fibroblasts by IDH3alpha downregulation. *Cell Rep* **10**, 1335–1348.
13 Wei Z, Cui L, Mei Z, Liu M and Zhang D (2014) miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway. *FEBS Lett* **588**, 1773–1779.
14 Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ and Fernández-Hernando C (2010) MiR-33 contributes to the regulation of cholesterol homeostasis. *Science* **328**, 1570–1573.
15 Liu Q, Liao F, Wu H, Cai T, Yang L, Wang ZF and Zou R (2014) Upregulation of miR-132 expression in glioma and its clinical significance. *Tumour Biol* **35**, 12299–12304.
16 Yang J, Gao T, Tang J, Cai H, Lin L and Fu S (2013) Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. *Mol Cell Biochem* **381**, 9–15.
17 Zhang B, Lu L, Zhang X, Ye W, Wu J, Xi Q and Zhang X (2014) Hsa-miR-132 regulates apoptosis in non-small cell lung cancer independent of acetylcholinesterase. *J Mol Neurosci* **53**, 335–344.
18 Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H *et al.* (2013) Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. *Cancer Res* **73**, 1232–1244.
19 Treiber T, Treiber N and Meister G (2012) Regulation of microRNA biogenesis and function. *Thromb Haemost* **107**, 605–610.
20 Deng JH, Deng Q, Kuo CH, Delaney SW and Ying SY (2013) miRNA targets of prostate cancer. *Methods Mol Biol* **936**, 357–369.
21 Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R and Haqq C (2006) Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. *Mol Cancer* **5**, 24.
22 Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, Stephens RM, Liu CG, Calin GA *et al.* (2008) Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. *Prostate* **68**, 1152–1164.
23 Zhang ZG, Chen WX, Wu YH, Liang HF and Zhang BX (2014) MiR-132 inhibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. *Biochem Biophys Res Commun* **454**, 109–114.
24 Renjie W and Haiqian L (2015) MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. *Cancer Lett* **356**, 568–578.